An Introduction to Danny Thomas |
Saint Jude's Today
Even today, Saint Jude's is a growing organization that provides care to cancer patients. They have also been extensively researching ways in which they can help people.
"Tri Delta strives to teach its members to be steadfast in our love for others and unselfish in leadership. Our partnership with St. Jude Children's Research Hospital has continued to show us the amazing things we can accomplish when we incorporate these qualities into our work," said Tri Delta Fraternity President Phyllis Durbin Grissom, Southern Methodist. "Our hope is that the families who stay at Tri Delta Place will feel comforted by the love and support of Tri Delta." (St. Jude Children's Research Hospital, "St. Jude Children's Research," Medical News.)
Saint Jude Children's Research Hospital is one of the leading hospitals in cancer research. This excerpt is an example of all the research and work that is being done at the hospital.
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer. St. Jude Children's Research Hospital scientists led the study, which is being published online today in the Journal of Clinical Oncology. Researchers reported that patients who inherited either one or two copies of the newly identified variation in the NUDT15 gene were extremely sensitive to the drug mercaptopurine. Patients with the NUDT15 variant required a mercaptopurine dose reduction of as much as 92 percent. At standard doses patients developed side effects that caused treatment delays and threatened their chances of cures.The finding should aid efforts to improve identification and treatment of patients who need reduced doses of mercaptopurine. Mercaptopurine is the backbone of chemotherapy that has helped transform the outlook for young ALL patients. At St. Jude, 94 percent of newly diagnosed ALL patients now become long-term survivors. (Strehlau, "Inherited gene variation helps," MedicalPress.
Today, Saint Jude's is under the leadership of James Downing, MD. Downing is the President and CEO of Saint Jude Children's Research Hospital.
So many people have been inspired by Saint Jude's and many famous celebrities are spreading the mission of Saint Jude Children's Research Hospital. With the help of donations, Saint Jude's has the ability to keeps its facilities running and to the best that they can possibly be. One little promise to a saint, changed the world completely by opening the doors to the development of cancer care and research.
"Tri Delta strives to teach its members to be steadfast in our love for others and unselfish in leadership. Our partnership with St. Jude Children's Research Hospital has continued to show us the amazing things we can accomplish when we incorporate these qualities into our work," said Tri Delta Fraternity President Phyllis Durbin Grissom, Southern Methodist. "Our hope is that the families who stay at Tri Delta Place will feel comforted by the love and support of Tri Delta." (St. Jude Children's Research Hospital, "St. Jude Children's Research," Medical News.)
Saint Jude Children's Research Hospital is one of the leading hospitals in cancer research. This excerpt is an example of all the research and work that is being done at the hospital.
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer. St. Jude Children's Research Hospital scientists led the study, which is being published online today in the Journal of Clinical Oncology. Researchers reported that patients who inherited either one or two copies of the newly identified variation in the NUDT15 gene were extremely sensitive to the drug mercaptopurine. Patients with the NUDT15 variant required a mercaptopurine dose reduction of as much as 92 percent. At standard doses patients developed side effects that caused treatment delays and threatened their chances of cures.The finding should aid efforts to improve identification and treatment of patients who need reduced doses of mercaptopurine. Mercaptopurine is the backbone of chemotherapy that has helped transform the outlook for young ALL patients. At St. Jude, 94 percent of newly diagnosed ALL patients now become long-term survivors. (Strehlau, "Inherited gene variation helps," MedicalPress.
Today, Saint Jude's is under the leadership of James Downing, MD. Downing is the President and CEO of Saint Jude Children's Research Hospital.
So many people have been inspired by Saint Jude's and many famous celebrities are spreading the mission of Saint Jude Children's Research Hospital. With the help of donations, Saint Jude's has the ability to keeps its facilities running and to the best that they can possibly be. One little promise to a saint, changed the world completely by opening the doors to the development of cancer care and research.